Cardio-Nephrology

Image

Journal of Clinical Nephrology and Therapeutics publishes the manuscripts that are directly or indirectly based on variegated aspects of clinical nephrology, diabetic nephropathy, pediatric nephrology, renal physiology, renal histopathology, immunobiology, intensive care nephrology, and ischemic nephropathy.

Cardio-Nephrology: The need for more collaborative efforts between therapeutic clinical trials and social health sciences to preclude cardiovascular disease complications in renal patients. Cardiology and Nephrology specialties share several elements in the prevention of Cardiovascular Disease (CVD). CVD prevention in patients with CKD (Chronic Kidney Disease) can only really be understood if there are more robust collaborative clinical trials, and social sciences health research between nephrology and cardiology, not only to inform healthcare and best practices, but also to inform healthcare innovation. More than 80% of renal patients have one or more cardiovascular risk factors. Randomized Controlled Trials (RCTs) and social science research information that compromised cardiac health is a key source of demise in patients. The aim here is to highlight the need for more robust collaborations between Nephrology, Cardiology and Therapeutic clinical trials, to preclude CVD complications in renal patients. Chemokine receptors are expressed on cell populations, permitting different chemokines to have selective activity. Chemokine is primarily involved in the attraction of leukocytes. CVD intervention takes many forms but begins at acknowledging a need for more targeted therapeutics. Haemodialysis aggravates patient prognosis and myocardial function. Health awareness and education are still a much-needed resource for renal patients; more awareness and comprehension of CVD implemented as part of a patient’s health plan. Now more than ever there needs to be a closer link between clinical trials between the two medical specialties, and social sciences to inform how best to prevent patients with CKD developing CVD events.

Measuring endothelial function, providing nutrition and physical activity advice to prevent CVD and MI risks are just a few traditional interventional measures [58,78,79]; innovative screening, imaging, and technology can also assist patients and teams [48-53]. Compared to later reviews surrounding this subject, this paper highlights given that patients are being prompted more to self-care through technology, now more than ever there needs to be a closer link between randomized clinical trials between the cardio-nephrology specialties, and social sciences to inform how best to prevent patients with CKD developing CVD events.

Articles that are submitted to our journal will undergo a double-blind peer-review process to maintain quality and the standards set for academic journals.  After acceptance by the editor, it will be published on the Press page.  Authors can submit their manuscripts to the online submission portal.

Best Regards,
Anna Melissa
Editorial Manager
Journal of Clinical Nephrology and Therapeutics